Display options
Cite
Ng CS, Lee JY, Toh MP, et al. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2014;105(2):151-63doi: 10.1016/j.diabres.2014.03.020.
Ng, C. S., Lee, J. Y., Toh, M. P., & Ko, Y. (2014). Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes research and clinical practice, 105(2), 151-63. https://doi.org/10.1016/j.diabres.2014.03.020
Ng, Charmaine S, et al. "Cost-of-illness studies of diabetes mellitus: a systematic review." Diabetes research and clinical practice vol. 105,2 (2014): 151-63. doi: https://doi.org/10.1016/j.diabres.2014.03.020
Ng CS, Lee JY, Toh MP, Ko Y. Cost-of-illness studies of diabetes mellitus: a systematic review. Diabetes Res Clin Pract. 2014 Aug;105(2):151-63. doi: 10.1016/j.diabres.2014.03.020. Epub 2014 Apr 18. PMID: 24814877.
Copy Download .nbib Format: NLM
Share it on

Diabetes Res Clin Pract. 2014 Aug;105(2):151-63. doi: 10.1016/j.diabres.2014.03.020. Epub 2014 Apr 18.

Cost-of-illness studies of diabetes mellitus: a systematic review.

Diabetes research and clinical practice

Charmaine S Ng, Joyce Y C Lee, Matthias Phs Toh, Yu Ko

Affiliations

  1. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.
  2. Information Management, Corporate Development, National Healthcare Group, Singapore, Singapore; Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore.
  3. Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore. Electronic address: [email protected].

PMID: 24814877 DOI: 10.1016/j.diabres.2014.03.020

Abstract

BACKGROUND: Diabetes mellitus (DM) is recognised as a major health problem.

OBJECTIVES: The aims of this study are two-fold: (1) to describe the methods used in the identified cost-of-illness (COI) studies of DM and (2) to summarise their study findings regarding the economic impact of DM.

METHODS: This is a systematic review of MEDLINE and Scopus journal articles reporting the cost of type 1 and/or 2 DM that were published in English from 2007 to 2011. Costs reported in the included studies were converted to US dollars.

RESULTS: The systematic search yielded 30 articles. The studies varied considerably in their study design, perspective and included cost categories. Estimates for the total annual costs of DM ranged from US$141.6 million to US$174 billion; direct costs ranged from US$150 to US$14,060 per patient per year (pppy) whereas indirect costs ranged from US$39.6 to US$7,164 pppy. Inpatient cost was the major contributor to direct cost in half of the studies that included inpatient costs, physician services and medications.

CONCLUSION: There is a considerable economic burden associated with DM. Future research should focus on improving methods of estimating costs, enhancing the interpretation of study findings and facilitating comparisons between studies.

Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Keywords: Cost analysis; Cost of disease; Cost-of-illness; Diabetes; Economic burden; Healthcare costs

MeSH terms

Publication Types